EP0399444A1 - New carcinostatic or antitumor antibiotic, conagenin, and production and uses thereof - Google Patents
New carcinostatic or antitumor antibiotic, conagenin, and production and uses thereof Download PDFInfo
- Publication number
- EP0399444A1 EP0399444A1 EP90109658A EP90109658A EP0399444A1 EP 0399444 A1 EP0399444 A1 EP 0399444A1 EP 90109658 A EP90109658 A EP 90109658A EP 90109658 A EP90109658 A EP 90109658A EP 0399444 A1 EP0399444 A1 EP 0399444A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- conagenin
- antibiotic
- strain
- culture
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GLESHRYLRAOJPS-DHCFDGJBSA-N conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 title claims abstract description 82
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 230000003327 cancerostatic effect Effects 0.000 title abstract description 17
- 239000003972 antineoplastic antibiotic Substances 0.000 title description 4
- 201000009030 Carcinoma Diseases 0.000 claims abstract description 24
- 230000003115 biocidal effect Effects 0.000 claims abstract description 15
- 244000005700 microbiome Species 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 241000187747 Streptomyces Species 0.000 claims abstract description 10
- 241000958215 Streptomyces filamentosus Species 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 238000000855 fermentation Methods 0.000 claims abstract description 5
- 230000004151 fermentation Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 229920001817 Agar Polymers 0.000 description 20
- 239000008272 agar Substances 0.000 description 20
- 239000000049 pigment Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 239000008273 gelatin Substances 0.000 description 9
- 229920000159 gelatin Polymers 0.000 description 9
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108010062580 Concanavalin A Proteins 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 241000186046 Actinomyces Species 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- OKKJLVBELUTLKV-MICDWDOJSA-N deuteriomethanol Chemical compound [2H]CO OKKJLVBELUTLKV-MICDWDOJSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 241000544912 Melanoides Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- -1 alkali metal salts Chemical class 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 2
- 229940016114 calcium malate Drugs 0.000 description 2
- 239000001362 calcium malate Substances 0.000 description 2
- 235000011038 calcium malates Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000012773 waffles Nutrition 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241001468243 Streptomyces roseofulvus Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- UGZVBQBZBBMPMB-UHFFFAOYSA-N acetic acid butan-1-ol butyl acetate hydrate Chemical compound O.CC(O)=O.CCCCO.CCCCOC(C)=O UGZVBQBZBBMPMB-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003254 anti-foaming effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Definitions
- This invention relates to a new antibiotic, Conagenin, which exhibits a useful carcinostatic or antitumor activity and a process for the production thereof.
- This invention also relates to a pharmaceutical composition containing Conagenin as active ingredient which is useful as carcinostatic or antitumor agent and a method of inhibitingly treating carcinomas or tumors, particularly malignant tumors of mammalian animals including man therewith.
- This invention also includes a new microorganism which is useful for the production of the new antibiotic Conagenin.
- a main object of this invention is to provide a new carcinostatic or antitumor antibiotic, Conagenin.
- Another object of this invention is to provide a process for the production of Conagenin.
- a further object of this invention is to provide a pharmaceutical composition containing Conagenin as active ingredient.
- a yet further object of this invention is to provide a method of inhibitingly treating carcinomas or malignant tumors of mammalian animals including man with Conagenin.
- a still further object of this invention is to provide a new microorganism which can produce Conagenin.
- salts of Conagenin include metal salts at the carboxyl group of Conagenin, particularly alkali metal salts such as sodium and potassium salts and alkaline earth metal salts such as calcium salts.
- Conagenin is a new antibiotic substance that we, the present inventors, have now discovered as a result of our study on such substances which are active to increase binding of concanavalin A to the carcinoma cell membrane, with our intention of obtaining a useful carcinostatic substance which can exhibit its carcinostatic or antitumor activity through it nature of modifying the carcinoma cell membrane.
- Conagenin can exhibit a significant carcinostatic or antitumor activity in vivo , for example against Ehrlich's solid carcinoma in mice, with a low toxicity.
- Typical physico-chemical properties of Conagenin are as follows: (1) Appearance: Colorless plate crystals (2) Elemental analysis: C, 47.96%; H, 7.67%; N, 5.64%; O, 38.19% (3) Mass spectrum: m/z 250.1291(M+H)+ (by FAB high resolution mass spectrometry) (4) Molecular formula: C10H19NO6 (5) Melting point: 159 - 161°C (6) Specific rotation: [ ⁇ ] 27 D +55.4° (c 1.0, methanol) (7) Solubility: Easily soluble in methanol; soluble in water; but sparingly soluble in chloroform. (8) UV absorption spectrum (in methanol): Terminal absorption is observed.
- Conagenin has been determined to have the chemical structure of formula (I) above. Since no such compound that the structure thereof conforms to that of formula (I) has been reported yet, Conagenin is, we decided, to be a new antibiotic.
- a process for the production of an antibiotic, Conagenin which comprises cultivating a Conagenin-producing strain of the genus Streptomyces in a culture medium until a substantial amount of Conagenin is produced and accumulated in the culture, and then recovering Conagenin from the resulting culture.
- One typical example of Conagenin-producing strains of the genus Streptomyces to be used in the process of the second aspect of this invention is a new strain of Actinomycetes which was isolated from soil samples collected in Zushi, Kanagawa prefecture, Japan in February, 1988 and to which MI696-AF3 was assigned.
- the microbiological properties of MI696-AF3 strain are shown below:
- the growth is pale yellow in color and the aerial hyphae show white to pinkish white [3 ca, Pearl Pink] in color. No soluble pigment is observed.
- Aerial hyphae of pinkish white to pale pink [4 ca, Flesh Pink] in color are formed on the growth of pale yellowish brown [3 ie, Camel] to yellowish brown [3 le, Cinnamon] in color and the soluble pigment is yellowish brown.
- Aerial hyphae of pale pink [4 ca, Flesh Pink] in color are formed on the growth of pale yellow [2 ea, Lt Wheat] to pale yellowish brown [2 ic, Honey Gold] in color. No soluble pigment is observed.
- the growth is pale yellow [2 ea, Lt Wheat] to pale yellow brown [2 ic, Honey Gold] in color and the aerial hyphae show brownish white [3 ca, Pearl Pink] in color. No soluble pigment is observed.
- the growth is colorless without formation of aerial hyphae thereon. No soluble pigment is observed.
- Aerial hyphae of pale pink [4 ca, Flesh Pink to 5 ca, Flesh Pink] in color are formed on the growth of pale yellowish brown [2 ic, Honey Gold to 3 le, Cinnamon] in color. No soluble pigment is observed.
- the growth is colorless and the aerial hyphae is pinkish white to pale pink [4 ca, Flesh Pink to 5 ca, Flesh Pink] in color. No soluble pigment is observed.
- Aerial hyphae of brownish white [3 ca, Pearl Pink] in color are formed on the growth of pale yellow [11 ⁇ 2 ea, Lt Yellow] to yellowish brown [3 ng, Yellow Maple] in color. A little of soluble pigment of yellowish brown color is observed.
- the growth is pale yellow to pale yellowish brown [2 gc, bamboo] in color and the aerial hyphae is pale pink [4 ca, Flesh Pink] in color. No soluble pigment is observed.
- the growth is colorless without formation of aerial hyphae.
- the soluble pigment is slightly brown tinged.
- Liquefaction was started at about 7th day of the incubation in the simple gelatin medium and at about 11th day of the incubation in the glucose-peptone-gelatin medium.
- the grade of liquefaction is medium or rather stronger in the former and is slow and medium in the latter.
- Peptonization was started at about 8th day of incubation with no occurrence of coagulation. The progress of coagulation is slow and completed in the 3rd week from the start thereof.
- the melanoid-formation was negative in each of the culture media tested.
- D-glucose, L-arabinose, D-xylose, rhamnose and lactose were well utilizable for the growth. Inositol, D-fructose, sucrose, D-mannitol and raffinose were not utilizable.
- the liquefaction was positive.
- nitrate aqueous peptone solution containing 0.1% potassium nitrate, ISP-medium 8, cultured at 27°C
- the decomposition was negative.
- the MI696-AF3 strain is morphologically characterized in that the aerial hyphae are straight in shape with no formation of spirals and whirls, and that the spore surface is smooth.
- aerial hyphae of pinkish white to pale pink in color are formed on the vegetable mycelium of colorless or of pale yellow to pale yellowish brown in color and no soluble pigment is produced in rather many cases, but sometimes such soluble pigment as slight brown tinged is observed.
- the formation of melanoid pigment is negative in any of trypton-yeast broth, peptone-yeast-iron agar and tyrosine-agar media.
- the grade of protein-decomposing activity is medium to strong and that of starch-decomposing activity is also strong. 2,6-Diaminopimelic acid present in the cell wall was of the LL-type.
- the MI696-AF3 strain closely resembles to both the species, Streptomyces roseoporus and Streptomyces roseofluvus .
- the MI696-AF3 strain is distinguished from Streptomyces roseofluvus in the utilization of D-fructose, sucrose and raffinose and in the soluble pigment.
- the MI696-AF3 strain and Steptomyces roseosporus are closely similar in all the properties tested.
- the MI696-AF3 strain has now been identified as Streptomyces roseosporus MI696-AF3.
- strain MI696-AF3 has been deposited in the Japanese depository "Fermentation Research Institute", Agency of Industrial Science and Technology (located in Tsukuba-shi, Ibaraki-ken, Japan), since 2nd March, 1989 under the deposit number "FERM P-10598” and now deposited under the deposit number "FERM BP-2738" in terms of the Budapest Treaty.
- Conagenin can exhibit a significant carcinostatic or antitimor activity with a low toxicity.
- Such useful biological properties of Conagenin have been confirmed experimentally by us, some of which are given below.
- Toxicity of Conagenin was tested by intraperitoneal administration to female ICR mice and estimated as its LD50 being higher than 50 mg/Kg.
- Control test was conducted using 8 mice of the same type as above in a usual manner.
- Percent inhibition of the proliferation of the solid carcinoma i.e. the percent decrease in the weight of the solid carcinoma in each treated group of mice administered with Conagenin as compared to that in the control group of mice (untreated), is callculated and shown in Table 3 below.
- Table 3 Dosage of Conagenin (mg/Kg/day) Percent inhibition (%) 6.25 45 3.1 67 1.56 44 0.78 58 0.39 29 0.195 44
- Leukemia L1210 cells were suspended in a 10% bovine serum-added minimum essential medium [MEM, a product of Nissui Pharmaceutical Co., Ltd.] to give a concentration of 2 x 105 cells/ml and Conagenin was added to the cell suspension so that the cell suspensions had a Conagenin concentration of 1 ⁇ g/ml, 0.5 ⁇ g/ml and 0.25 ⁇ g/ml, respectively.
- MEM bovine serum-added minimum essential medium
- Concanavalin A (Concanavalin A N-[acetyl-3H] acetylated; a product of Amersham Co., Ltd.) in an amount of 40 nCi/ml was added to the suspension under incubation at a time of one hour before the end of the incubation.
- the incubated cells were fixed on a filter paper by a cell harvester and the radioactivity value of the cells so fixed was measured by a liquid scintillation counter.
- the respective values thus given were converted assumed that the radioactivity value of the control group sample was amounting to 100, and the converted values are shown in Table 4 as the increase in binding of Concanavalin A to L1210 cells.
- a third aspect of this invention is a pharmaceutical composition
- a pharmaceutical composition comprising as active ingredient an antibiotic, Conagenin having formula (I) above, in combination with a pharmaceutically acceptable carrier or carriers for the active ingredient.
- the pharmaceutical composition according to this invention is effective and useful as carcinostatic or antitumor agent for mammalian animals, including man.
- the pharmaceutical composition according to this invention may be formulated in a conventional manner into any convenient form of medicinal preparations for oral, intraperitoneal or parenteral administration such as, for example, injections, tablets, capsules, granules, syrups, suppositories and ointments.
- pharmaceutically acceptable carriers there may be used any of known, conventional ones as desired.
- the nature and composition of carriers to be used may vary depending on the route and manner of administration and include organic and inorganic, solid and liquid, usually inert carriers and excepients known and available for pharmaceutical purposes.
- compositions of this invention may vary from 0.2 to 100% by weight, preferably from 1 to 90% by weight, based on the total weight of the composition.
- the pharmaceutical composition of this invention may contain, in addition to Conagenin, one or more other pharmacologically active ingredients including those having carcinostatic, antitumor and other pharmacological activities.
- the pharmaceutical composition according to this invention may be administered at a dosage capable of exhibiting a desired pharmacological activity without being accompanying with any appreciable side effect.
- Particular dosage is to be chosen by a medical man in each particular case, but the dosage of the active ingredient, Conagenin, will in general be a level in the range of 10 mg - 10 g, preferably 20 mg - 5 g, per day on adult patient for therapeutic treatments of carcinomas and malignent tumors.
- the pharmaceutical composition of this invention may conveniently be administered as a unit preparation containing 1 mg - 5 g, preferably 3 mg - 1 g of the active ingredient Conagenin.
- a method of inhibitingly treating carcinomas or malignant tumors of mammalian animals comprising administering an antibiotic Conagenin having formula (I) above, usually, in the form of a pharmaceutical composition, in a therapeutically effective amount to a mammalian animal having a carcinoma or malignant tumor.
- the dosage of Conagenin may suitably be determined by a medical man, typically with having regard to the age, body weight, sympton of patients and therapeutic purpose as intended.
- the effective dosage as indicated above can be administered continuously or intermittenlly as long as the total dosage does not exceed such a specific level as decided in view of results of animal tests and various circumstances.
- a Conagenin-producing strain preferably Streptomyces roseosporus MI696-AF3 strain (identified as the culture deposited under FERM BP-2738), is cultivated by a known and ordinary method for the cultivation of microorganisms of Actinomyces .
- Conagenin is produced and accumulated predominantly in the liquid phase of the culture broth.
- it is preferable that Conagenin is produced by cultivating the MI696-AF3 strain in a suitable culture medium under appropriate conditions.
- the culture medium used for the cultivation may contain assimilable carbon sources, assimilable nitrogen sources and inorganic salts, etc.
- the available carbon sources include those known materials such as mannose, glucose, galactose, maltose, peptone, dextrin, starch, millet, mollasses and soybean oils.
- the available nitrogen sources include those known materials such as soybean powder, meat extract, peptone, yeast extract, dried yeast, NZ-amine, nitrate, ammonium nitrate, ammonium sulfate and others.
- the inorganic salts may include sodium chloride, phosphates, calcium carbonate, magnesium sulfate, copper sulfate, iron sulfate, manganese chloride, zinc sulfate and other.
- the productive culture medium which may be used for commercial production of Conagenin may contain meat extract, peptone, yeast extract and some inorganic salts and, if desired, an anti-foaming agent such as animal oils, vegetable oils, etc. Further, any other organic and inorganic materials which are known as the ones used for activation of a microorganism of Actinomyces and are useful for the production of Conagenin may also advantageously be incorporated into the culture medium.
- the cultivation of the MI696-AF3 strain for the production of Conagenin may be conducted under aerobic conditions and preferably under submerged conditions.
- the cultivation of the Conagenin-producing strain may be effected in a range of temperatures where said strain can grow and produce a substantial amount of Conagenin, and the MI696-AF3 strain may be cultivated at a temperature of 25 to 40°C, preferably at a temperature of 30 to 37°C.
- the other conditions for the cultivation may suitably be chosen, depending on and according to the microbiological and physiological properties of the Conagenin-producing strain as employed.
- the recovery of Conagenin from the culture of the Conagenin-producing microorganism may be achieved with utilizing that Conagenin is a weakly acidic substance and is readily soluble in methanol, soluble in water but is insoluble in some organic solvent such as chloroform.
- the recovery of Conagenin from the culture of the Conagenin-producing microorganism is conducted by the following procedure.
- the culture obtained or the culture broth is filtered or centrifuged to remove the incubated cells of the microorganism, and the broth filtrate is mixed with activated carbon for adsorption of the active substance thereon.
- the activated carbon containing the adsorbed Conagenin therein is then extracted with 50% aqueous acetone.
- the resulting extract containing Conagenin is then concentrated under a reduced pressure to dryness, and the residue is dissolved in water, followed by extraction of the resulting aqueous solution with n-butanol.
- the extract in n-butanol is then again concentrated to dryness under a reduced pressure to give a residue comprising Conagenin.
- This crude product may then be partially purified by a silica gel column chromatography as developed with a mixed solvent of butyl acetate, n-butanol and water as eluent.
- Further purification of a partially pure product of Conagenin may be effected by a high performance liquid chromatography on a revese phase column of a sillylated silica gel and using a gradient elution method with 10% aqueous methanol to 100% methanol, so that the active fractions of the effluent containing only Conagenin as the active substance may be obtained.
- a pure solution of Conagenin in methanol is concentrated under a reduced pressure, Conagenin may be precipitated in the form of colorless crystals.
- This invention further provides, as a fifth aspect thereof, a new microorganism, Streptomyces roseosporus MI696-AF3 strain, which is identified as the culture deposited under the deposit number FERM BP-2738 in the "Fermentation Research Institute” and which is characterized by being capable of producing an antibiotic, Conagenin, which is a compound having formula (I) given above.
- a loopful amount of Streptomyces roseosporus MI696-AF3 strain (identified as FERM BP-2738) was taken from its agar slant culture and inoculated into 110 ml-portions of a liquid medium (pH7.4) containing 2.0% galactose, 2.0% dextrin, 1.0% soy-peptone (sold under Bactosoytion by Difco Co.), 0.5% corn steep liquor (a product of Japan Maize Products Co., Ltd.), 0.2% ammonium sulfate, 0.2% calcium carbonate and 0.03% antifoaming silicone oil (sold under Silicone KM70 by Shin-Etsu Chemical Co., Ltd.), of which each 100-ml portion had been placed in each of two Erlenmyer flasks filled with waffle.
- Each inoculated medium so prepared was cultivated under shaking at 27°C for 3 days.
- the seed culture thus obtained was inoculated in 3 ml-portions each into 110 ml-portions of a liquid culture medium comprising 2.0% maltose (a product of Hayashibara Biochemical Co., Ltd.), 0.5% meat extract for cultivation of bacteria (a product of Kyokuto Pharmaceutical Co., Ltd.), 0.5% peptone (polypeptone available from Nippon Pharmaceutical Co., Ltd.), 0.3% powdery yeast extract S (a product of Nippon Pharmaceutical Co., Ltd.), 0.3% sodium chloride and 0.1% magnesium sulfate (7H2O) as well as inorganic salts as incorporated in the form of 1.22 ml/l of a solution of 2.8 g of cupric sulfate (5H2O), 0.4 g of ferrous sulfate, 3.2 g of manganese chloride (4H2O) and 0.8 g of zinc sulfate (7H2O
- the oil so obtained was subjected to chromatography on a silica gel column (150 ml) using butyl acetate-butanol-acetic acid-water (6 : 4 : 1 : 1 by volume) as eluent.
- the resulting eluate was fractionated in a usual manner and there were collected such eluate fractions which showed Rf values of 0.50 - 0.55 on a silica gel thin layer chromatography [Art. 5715 silica gel plate made of Merck Co., eluent : butanol-acetic acid-water (4 : 1 : 1 by volume)] and which developed color with ninhydrine.
- the fractions so collected were concentrated in vacuo, affording 1.2 g of crude Conagenin product.
- the crude product was subjected to high performance liquid chromatography (Senshu Pack Nucleosil 5C18, 20 ⁇ x 300 mm, a product of Senshu Kagaku Co., Japan) at a flow rate of 5 ml/min with gradient elution such that the mobil phase is gradually changed from 10% aqueous methanol to 100% methanol during the period of 20 minutes, followed by elution with pure (100%) methanol for further 20 minutes.
- the effluents showing the peak over the period of 21 minutes. were fractionated and collected and the collected fractions were concentrated in vacuo, affording 34.8 mg of Conagenin as colorless crystals.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
- This invention relates to a new antibiotic, Conagenin, which exhibits a useful carcinostatic or antitumor activity and a process for the production thereof. This invention also relates to a pharmaceutical composition containing Conagenin as active ingredient which is useful as carcinostatic or antitumor agent and a method of inhibitingly treating carcinomas or tumors, particularly malignant tumors of mammalian animals including man therewith. This invention also includes a new microorganism which is useful for the production of the new antibiotic Conagenin.
- There are about 5,000 different antibiotics produced by microorganisms which have already been reported in the art, some of which have been used widely for the therapeutic treatments of carcinomas, tumors and other infections. Among metabolites of microorganisms belonging to the genus Streptomyces, actinomycin D, mitomycin C, bleomycin, daunomycin, adriamycin and acracinomycin are typical as those having been used as carcinostatic and antitumor agents.
- Nevertheless, it has always been demanded still further to discover or produce new carcinostatic or antitumor substances having a unique carcinostatic or antitumor activity which is different in mechanism of function from known, conventional carcinostatic or antitumor antibiotics and having a low toxicity and thus being capable of using for the therapeutic treatment of carcinomas and malignant tumors of man.
- Accordingly, a main object of this invention is to provide a new carcinostatic or antitumor antibiotic, Conagenin.
- Another object of this invention is to provide a process for the production of Conagenin.
- A further object of this invention is to provide a pharmaceutical composition containing Conagenin as active ingredient.
- A yet further object of this invention is to provide a method of inhibitingly treating carcinomas or malignant tumors of mammalian animals including man with Conagenin.
- A still further object of this invention is to provide a new microorganism which can produce Conagenin.
-
- Typical examples of salts of Conagenin include metal salts at the carboxyl group of Conagenin, particularly alkali metal salts such as sodium and potassium salts and alkaline earth metal salts such as calcium salts.
-
- Figure 1 is an infrared absorption spectrum of Conagenin pelleted in KBr tablet, in which the abscissa axis represents wave number (cm⁻¹) and the ordinate axis represents transmittance (%).
- Figure 2 is a proton nuclear magnetic resonance spectrum of Conagenin in deuteromethanol, in which the abscissa represents chemical shift (ppm) and tetramethylsilane was used as internal standard.
- Conagenin is a new antibiotic substance that we, the present inventors, have now discovered as a result of our study on such substances which are active to increase binding of concanavalin A to the carcinoma cell membrane, with our intention of obtaining a useful carcinostatic substance which can exhibit its carcinostatic or antitumor activity through it nature of modifying the carcinoma cell membrane. We have found that Conagenin can exhibit a significant carcinostatic or antitumor activity in vivo, for example against Ehrlich's solid carcinoma in mice, with a low toxicity.
- Typical physico-chemical properties of Conagenin are as follows:
(1) Appearance: Colorless plate crystals
(2) Elemental analysis:
C, 47.96%; H, 7.67%; N, 5.64%; O, 38.19%
(3) Mass spectrum:
m/z 250.1291(M+H)⁺ (by FAB high resolution mass spectrometry)
(4) Molecular formula: C₁₀H₁₉NO₆
(5) Melting point: 159 - 161°C
(6) Specific rotation: [α]
(7) Solubility: Easily soluble in methanol; soluble in water; but sparingly soluble in chloroform.
(8) UV absorption spectrum (in methanol): Terminal absorption is observed.
(9) IR absorption spectrum (KBr): Shown in Figure 1 of the appended drawings.
(10) NMR spectra:
(a) ¹H NMR specturm in deuteromethanol is shown as chemical shift (ppm) in Figure 2 of the appended drawings.
(b) ¹³C NMR spectrum in deuteromethanol is shown as chemical shift (ppm) in Table 1 given below.Table 1 176.7s 175.8s 75.3d 71.2d 66.2t 62.7s 43.7d 21.2q 20.0q 8.3q Note: s : singlet; d : doublet; t : triplet; q : quartet Internal standard : Tetramethylsilane - On the basis of the above-shown various spectra and X-ray diffraction analysis, Conagenin has been determined to have the chemical structure of formula (I) above. Since no such compound that the structure thereof conforms to that of formula (I) has been reported yet, Conagenin is, we decided, to be a new antibiotic.
- According to a second aspect of this invention, there is provided a process for the production of an antibiotic, Conagenin, which comprises cultivating a Conagenin-producing strain of the genus Streptomyces in a culture medium until a substantial amount of Conagenin is produced and accumulated in the culture, and then recovering Conagenin from the resulting culture.
- One typical example of Conagenin-producing strains of the genus Streptomyces to be used in the process of the second aspect of this invention is a new strain of Actinomycetes which was isolated from soil samples collected in Zushi, Kanagawa prefecture, Japan in February, 1988 and to which MI696-AF3 was assigned. The microbiological properties of MI696-AF3 strain are shown below:
- Microscopic observation shows that MI696-AF3 strain develops aerial hyphae from branched substrate mycelia and that the aerial hyphae are relatively long and straight in shape with no formation of spirals and whirls. At the tip of the aerial hyphae a chain of more than 50 spores is observed. The size of each spore is about 0.6 x 1.0 - 1.2 microns and the surface of the spores is smooth.
- The standard given in each of the brackets [ ] for the description of color is of "Color Harmony Mannual" of Container Corporation of America.
- White to pinkish white aerial hyphae are thinly formed on the colorless growth. No soluble pigment is observed.
- The growth is pale yellow in color and the aerial hyphae show white to pinkish white [3 ca, Pearl Pink] in color. No soluble pigment is observed.
-
- Aerial hyphae of pinkish white to pale pink [4 ca, Flesh Pink] in color are formed on the growth of pale yellowish brown [3 ie, Camel] to yellowish brown [3 le, Cinnamon] in color and the soluble pigment is yellowish brown.
- Aerial hyphae of pale pink [4 ca, Flesh Pink] in color are formed on the growth of pale yellow [2 ea, Lt Wheat] to pale yellowish brown [2 ic, Honey Gold] in color. No soluble pigment is observed.
- The growth is pale yellow [2 ea, Lt Wheat] to pale yellow brown [2 ic, Honey Gold] in color and the aerial hyphae show brownish white [3 ca, Pearl Pink] in color. No soluble pigment is observed.
- The growth is colorless without formation of aerial hyphae thereon. No soluble pigment is observed.
- Aerial hyphae of pale pink [4 ca, Flesh Pink to 5 ca, Flesh Pink] in color are formed on the growth of pale yellowish brown [2 ic, Honey Gold to 3 le, Cinnamon] in color. No soluble pigment is observed.
-
- The growth is colorless and the aerial hyphae is pinkish white to pale pink [4 ca, Flesh Pink to 5 ca, Flesh Pink] in color. No soluble pigment is observed.
- Aerial hyphae of brownish white [3 ca, Pearl Pink] in color are formed on the growth of pale yellow [1½ ea, Lt Yellow] to yellowish brown [3 ng, Yellow Maple] in color. A little of soluble pigment of yellowish brown color is observed.
- The growth is pale yellow to pale yellowish brown [2 gc, Bamboo] in color and the aerial hyphae is pale pink [4 ca, Flesh Pink] in color. No soluble pigment is observed.
- White aerial hyphae are formed on the colorless growth. No soluble pigment is observed.
- White aerial hyphae are thinly formed on the colorless growth. No soluble pigment is observed.
- In both a 15% simple gelatin culture medium (cultured at 20°C) and a glucose-peptone-gelatin culture medium (cultured at 27°C), the growth is colorless without formation of aerial hyphae. No soluble pigment is observed.
- The growth is colorless without formation of aerial hyphae. The soluble pigment is slightly brown tinged.
- In the tests which were conducted on a starch-yeast-agar medium comprising 1% of soluble starch, 0.2% of yeast extract (a product of Nippon Pharmaceutical Co., Ltd.) and 3.0% of stringe agar and having pH of 7.0 to 7.2 at varying temperatures, namely 20°C, 24°C, 27°C, 30°C, 37°C and 50°C, the growing of the strain occurred at any of temperatures tested except at 50°C. It appears that the optimum growth temperature is in the range of 30°C to 37°C.
- Liquefaction was started at about 7th day of the incubation in the simple gelatin medium and at about 11th day of the incubation in the glucose-peptone-gelatin medium. The grade of liquefaction is medium or rather stronger in the former and is slow and medium in the latter.
- Hydrolysis was observed to have been started at about 3rd day of the incubation in both the media, where the grade of hydrolysis is rather strong.
- Peptonization was started at about 8th day of incubation with no occurrence of coagulation. The progress of coagulation is slow and completed in the 3rd week from the start thereof.
- The melanoid-formation was negative in each of the culture media tested.
- D-glucose, L-arabinose, D-xylose, rhamnose and lactose were well utilizable for the growth. Inositol, D-fructose, sucrose, D-mannitol and raffinose were not utilizable.
- The liquefaction was positive.
-
- The reduction was positive.
- The decomposition was negative.
- Summarizing the microbiological properties given above, the MI696-AF3 strain is morphologically characterized in that the aerial hyphae are straight in shape with no formation of spirals and whirls, and that the spore surface is smooth. In various culture media, aerial hyphae of pinkish white to pale pink in color are formed on the vegetable mycelium of colorless or of pale yellow to pale yellowish brown in color and no soluble pigment is produced in rather many cases, but sometimes such soluble pigment as slight brown tinged is observed. The formation of melanoid pigment is negative in any of trypton-yeast broth, peptone-yeast-iron agar and tyrosine-agar media. The grade of protein-decomposing activity is medium to strong and that of starch-decomposing activity is also strong. 2,6-Diaminopimelic acid present in the cell wall was of the LL-type.
- In view of the microbiological properties described above, we have judged that the MI696-AF3 strain belongs to the genus Streptomyces. Then, the search of analogous known species with reference to the properties of the MI696-AF3 strain revealed Streptomyces roseofulvus [Literature 1, "International Journal of Systematic Bacteriology", Vol. 18, p.165 (1968);
Literature 2, "International Journal of Systematic Bacteriology", Vol. 30, P.399 (1980)] and Streptomyces roseosporus [Literature "International Journal of Systematic Bacteriology", Vol. 18, P.370 (1968)] as being the most analogous known strains. Thus, comparison was made on the properties between the MI696-AF3 strain and the two known strains, Streptomyces roseofluvus and Streptomyces roseosporus as summarized in Table 2 below. - As can be seen from Table 2 above, the MI696-AF3 strain closely resembles to both the species, Streptomyces roseoporus and Streptomyces roseofluvus. However, the MI696-AF3 strain is distinguished from Streptomyces roseofluvus in the utilization of D-fructose, sucrose and raffinose and in the soluble pigment. On the other hand, the MI696-AF3 strain and Steptomyces roseosporus are closely similar in all the properties tested. Thus, the MI696-AF3 strain has now been identified as Streptomyces roseosporus MI696-AF3.
- The strain MI696-AF3 has been deposited in the Japanese depository "Fermentation Research Institute", Agency of Industrial Science and Technology (located in Tsukuba-shi, Ibaraki-ken, Japan), since 2nd March, 1989 under the deposit number "FERM P-10598" and now deposited under the deposit number "FERM BP-2738" in terms of the Budapest Treaty.
- As already mentioned briefly, Conagenin can exhibit a significant carcinostatic or antitimor activity with a low toxicity. Such useful biological properties of Conagenin have been confirmed experimentally by us, some of which are given below.
- Toxicity of Conagenin was tested by intraperitoneal administration to female ICR mice and estimated as its LD₅₀ being higher than 50 mg/Kg.
- (2) Inhibitory activity on Ehrlich's solid carcinoma in mice ICR mice (female, 6 weeks-aged, 4 mice in each group) were inoculated with Ehrlich's ascites carcinoma cells (2 x 10⁶ per mouse in the form of a cell suspension) subcutaneously at the groin of the mice. After the 7th day from the inoculation of the carcinoma cells, an injectable solution of Conagenin was intraperitoneally injected into the carcinoma-bearing mice at a dosage of 6.25, 3.1, 1.56, 0.78, 0.39 and 0.195 mg/Kg once a day during the consecutive 7 days for each group of mice. On the 15th day from the inoculation of the carcinoma cells, the solid carcinoma so grown was cut off and the weight of the solid carcinoma was determined. Control test was conducted using 8 mice of the same type as above in a usual manner. Percent inhibition of the proliferation of the solid carcinoma, i.e. the percent decrease in the weight of the solid carcinoma in each treated group of mice administered with Conagenin as compared to that in the control group of mice (untreated), is callculated and shown in Table 3 below.
Table 3 Dosage of Conagenin (mg/Kg/day) Percent inhibition (%) 6.25 45 3.1 67 1.56 44 0.78 58 0.39 29 0.195 44 - Leukemia L1210 cells were suspended in a 10% bovine serum-added minimum essential medium [MEM, a product of Nissui Pharmaceutical Co., Ltd.] to give a concentration of 2 x 10⁵ cells/mℓ and Conagenin was added to the cell suspension so that the cell suspensions had a Conagenin concentration of 1 µg/mℓ, 0.5 µg/mℓ and 0.25µg/mℓ, respectively. Each of the resulting suspensions was incubated in a CO₂-incubator (CO₂ concentration : 5%) at 37°C for 2 days. A radioisotope-labelled Concanavalin A (Concanavalin A N-[acetyl-³H] acetylated; a product of Amersham Co., Ltd.) in an amount of 40 nCi/mℓ was added to the suspension under incubation at a time of one hour before the end of the incubation. The incubated cells were fixed on a filter paper by a cell harvester and the radioactivity value of the cells so fixed was measured by a liquid scintillation counter. The respective values thus given were converted assumed that the radioactivity value of the control group sample was amounting to 100, and the converted values are shown in Table 4 as the increase in binding of Concanavalin A to L1210 cells. As is clear from Table 4, Conagenin could increase the binding of Concanavalin A to L1210 cells.
Table 4 Concentration of Conagenin (µg/mℓ) Increase in binding of Concanavalin A 1.0 121 0.5 129 0.25 <100 - On the basis of such useful biological properties of Conagenin as given above, a third aspect of this invention is a pharmaceutical composition comprising as active ingredient an antibiotic, Conagenin having formula (I) above, in combination with a pharmaceutically acceptable carrier or carriers for the active ingredient. The pharmaceutical composition according to this invention is effective and useful as carcinostatic or antitumor agent for mammalian animals, including man.
- The pharmaceutical composition according to this invention may be formulated in a conventional manner into any convenient form of medicinal preparations for oral, intraperitoneal or parenteral administration such as, for example, injections, tablets, capsules, granules, syrups, suppositories and ointments. As pharmaceutically acceptable carriers, there may be used any of known, conventional ones as desired. The nature and composition of carriers to be used may vary depending on the route and manner of administration and include organic and inorganic, solid and liquid, usually inert carriers and excepients known and available for pharmaceutical purposes. Some concrete examples of such carriers are crystalline cellulose, gelatin, lactose, starch, magnesium stearate, talc, vegetable and animal fats and oils, gums and polyalkylene glycols among others. The concentration of the active carcinostatic or antitumor ingredient, Conagenin, in the pharmaceutical composition of this invention may vary from 0.2 to 100% by weight, preferably from 1 to 90% by weight, based on the total weight of the composition. If desired, the pharmaceutical composition of this invention may contain, in addition to Conagenin, one or more other pharmacologically active ingredients including those having carcinostatic, antitumor and other pharmacological activities.
- The pharmaceutical composition according to this invention may be administered at a dosage capable of exhibiting a desired pharmacological activity without being accompanying with any appreciable side effect. Particular dosage is to be chosen by a medical man in each particular case, but the dosage of the active ingredient, Conagenin, will in general be a level in the range of 10 mg - 10 g, preferably 20 mg - 5 g, per day on adult patient for therapeutic treatments of carcinomas and malignent tumors. In these cases, the pharmaceutical composition of this invention may conveniently be administered as a unit preparation containing 1 mg - 5 g, preferably 3 mg - 1 g of the active ingredient Conagenin.
- Thus, according to a fourth aspect of this invention, there is provided a method of inhibitingly treating carcinomas or malignant tumors of mammalian animals, including man, which comprises administering an antibiotic Conagenin having formula (I) above, usually, in the form of a pharmaceutical composition, in a therapeutically effective amount to a mammalian animal having a carcinoma or malignant tumor.
- As already mentioned briefly, the dosage of Conagenin may suitably be determined by a medical man, typically with having regard to the age, body weight, sympton of patients and therapeutic purpose as intended. The effective dosage as indicated above can be administered continuously or intermittenlly as long as the total dosage does not exceed such a specific level as decided in view of results of animal tests and various circumstances.
- The fermentative production of Conagenin of this invention is now described.
- In carrying out the process for the production of Conagenin according to the second aspect of this invention, a Conagenin-producing strain, preferably Streptomyces roseosporus MI696-AF3 strain (identified as the culture deposited under FERM BP-2738), is cultivated by a known and ordinary method for the cultivation of microorganisms of Actinomyces. Conagenin is produced and accumulated predominantly in the liquid phase of the culture broth. In this process, it is preferable that Conagenin is produced by cultivating the MI696-AF3 strain in a suitable culture medium under appropriate conditions. The culture medium used for the cultivation may contain assimilable carbon sources, assimilable nitrogen sources and inorganic salts, etc. which are customarily used for the cultivation of Actinomyces. The available carbon sources include those known materials such as mannose, glucose, galactose, maltose, peptone, dextrin, starch, millet, mollasses and soybean oils. The available nitrogen sources include those known materials such as soybean powder, meat extract, peptone, yeast extract, dried yeast, NZ-amine, nitrate, ammonium nitrate, ammonium sulfate and others. The inorganic salts may include sodium chloride, phosphates, calcium carbonate, magnesium sulfate, copper sulfate, iron sulfate, manganese chloride, zinc sulfate and other.
- The productive culture medium which may be used for commercial production of Conagenin may contain meat extract, peptone, yeast extract and some inorganic salts and, if desired, an anti-foaming agent such as animal oils, vegetable oils, etc. Further, any other organic and inorganic materials which are known as the ones used for activation of a microorganism of Actinomyces and are useful for the production of Conagenin may also advantageously be incorporated into the culture medium.
- The cultivation of the MI696-AF3 strain for the production of Conagenin may be conducted under aerobic conditions and preferably under submerged conditions. The cultivation of the Conagenin-producing strain may be effected in a range of temperatures where said strain can grow and produce a substantial amount of Conagenin, and the MI696-AF3 strain may be cultivated at a temperature of 25 to 40°C, preferably at a temperature of 30 to 37°C. The other conditions for the cultivation may suitably be chosen, depending on and according to the microbiological and physiological properties of the Conagenin-producing strain as employed.
- In general, the recovery of Conagenin from the culture of the Conagenin-producing microorganism may be achieved with utilizing that Conagenin is a weakly acidic substance and is readily soluble in methanol, soluble in water but is insoluble in some organic solvent such as chloroform. Principally, it is preferred that the recovery of Conagenin from the culture of the Conagenin-producing microorganism is conducted by the following procedure. Thus, the culture obtained or the culture broth is filtered or centrifuged to remove the incubated cells of the microorganism, and the broth filtrate is mixed with activated carbon for adsorption of the active substance thereon. The activated carbon containing the adsorbed Conagenin therein is then extracted with 50% aqueous acetone. The resulting extract containing Conagenin is then concentrated under a reduced pressure to dryness, and the residue is dissolved in water, followed by extraction of the resulting aqueous solution with n-butanol. The extract in n-butanol is then again concentrated to dryness under a reduced pressure to give a residue comprising Conagenin. This crude product may then be partially purified by a silica gel column chromatography as developed with a mixed solvent of butyl acetate, n-butanol and water as eluent. Further purification of a partially pure product of Conagenin may be effected by a high performance liquid chromatography on a revese phase column of a sillylated silica gel and using a gradient elution method with 10% aqueous methanol to 100% methanol, so that the active fractions of the effluent containing only Conagenin as the active substance may be obtained. When a pure solution of Conagenin in methanol is concentrated under a reduced pressure, Conagenin may be precipitated in the form of colorless crystals.
- This invention further provides, as a fifth aspect thereof, a new microorganism, Streptomyces roseosporus MI696-AF3 strain, which is identified as the culture deposited under the deposit number FERM BP-2738 in the "Fermentation Research Institute" and which is characterized by being capable of producing an antibiotic, Conagenin, which is a compound having formula (I) given above.
- The following Example illustrates a typical process for the production of Conagenin, but it does not limit this invention thereto.
-
- A loopful amount of Streptomyces roseosporus MI696-AF3 strain (identified as FERM BP-2738) was taken from its agar slant culture and inoculated into 110 mℓ-portions of a liquid medium (pH7.4) containing 2.0% galactose, 2.0% dextrin, 1.0% soy-peptone (sold under Bactosoytion by Difco Co.), 0.5% corn steep liquor (a product of Japan Maize Products Co., Ltd.), 0.2% ammonium sulfate, 0.2% calcium carbonate and 0.03% antifoaming silicone oil (sold under Silicone KM70 by Shin-Etsu Chemical Co., Ltd.), of which each 100-mℓ portion had been placed in each of two Erlenmyer flasks filled with waffle. Each inoculated medium so prepared was cultivated under shaking at 27°C for 3 days. The seed culture thus obtained was inoculated in 3 mℓ-portions each into 110 mℓ-portions of a liquid culture medium comprising 2.0% maltose (a product of Hayashibara Biochemical Co., Ltd.), 0.5% meat extract for cultivation of bacteria (a product of Kyokuto Pharmaceutical Co., Ltd.), 0.5% peptone (polypeptone available from Nippon Pharmaceutical Co., Ltd.), 0.3% powdery yeast extract S (a product of Nippon Pharmaceutical Co., Ltd.), 0.3% sodium chloride and 0.1% magnesium sulfate (7H₂O) as well as inorganic salts as incorporated in the form of 1.22 mℓ/ℓ of a solution of 2.8 g of cupric sulfate (5H₂O), 0.4 g of ferrous sulfate, 3.2 g of manganese chloride (4H₂O) and 0.8 g of zinc sulfate (7H₂O) in 500 mℓ of distilled water, with each 110 mℓ- portion of said liquid culture medium being placed in each of 91 Erlenmyer flasks fitted with waffle. Each inoculated culture medium so obtained was incubated under shaking at 27°C for 4 days. The resulting culture broth was filtered to recover the culture broth filtrate. To the filtrate (8100 mℓ) was added activated carbon 200 g, followed by filtration. The active ingredient substance thus adsorbed on the activated carbon was extracted with 4ℓ of 50% aqueous acetone and the resulting extract was concentrated in vacuo. The concentrated residue was dissolved in 2ℓ of distilled water and the aqueous solution was extracted with the same volume of butanol at pH of 3. The butanol extract, after adjustment of the pH to 8, was concentrated in vacuo to yield 7.5 g of a brown oil.
- The oil so obtained was subjected to chromatography on a silica gel column (150 mℓ) using butyl acetate-butanol-acetic acid-water (6 : 4 : 1 : 1 by volume) as eluent. The resulting eluate was fractionated in a usual manner and there were collected such eluate fractions which showed Rf values of 0.50 - 0.55 on a silica gel thin layer chromatography [Art. 5715 silica gel plate made of Merck Co., eluent : butanol-acetic acid-water (4 : 1 : 1 by volume)] and which developed color with ninhydrine. The fractions so collected were concentrated in vacuo, affording 1.2 g of crude Conagenin product.
- The crude product was subjected to high performance liquid chromatography (Senshu Pack Nucleosil 5C₁₈, 20 ⌀ x 300 mm, a product of Senshu Kagaku Co., Japan) at a flow rate of 5 mℓ/min with gradient elution such that the mobil phase is gradually changed from 10% aqueous methanol to 100% methanol during the period of 20 minutes, followed by elution with pure (100%) methanol for further 20 minutes. The effluents showing the peak over the period of 21 minutes. were fractionated and collected and the collected fractions were concentrated in vacuo, affording 34.8 mg of Conagenin as colorless crystals. A methanol solution of this crystalline substance gave a single spot on a silica gel thin chromatography [Art. 5715 silica gel, a product of Merck Co.] using butanol-acetic acid-water (4 : 1 : 1 by volume) as the developer. Apparently, this can suggest that the product finally obtained was a pure Conagenin.
- The features disclosed in the foregoing description, in the claims and/or in the accompanying drawings may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.
Claims (6)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP127846/89 | 1989-05-23 | ||
JP1127846A JP2837870B2 (en) | 1989-05-23 | 1989-05-23 | Novel anticancer antibiotic conagenin and its production method |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0399444A1 true EP0399444A1 (en) | 1990-11-28 |
EP0399444B1 EP0399444B1 (en) | 1994-01-12 |
Family
ID=14970117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90109658A Expired - Lifetime EP0399444B1 (en) | 1989-05-23 | 1990-05-21 | New carcinostatic or antitumor antibiotic, conagenin, and production and uses thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US5098935A (en) |
EP (1) | EP0399444B1 (en) |
JP (1) | JP2837870B2 (en) |
CA (1) | CA2017276C (en) |
DE (1) | DE69005899T2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0617009A1 (en) * | 1992-10-15 | 1994-09-28 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Novel amino acid derivative |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4078397B2 (en) * | 1994-10-14 | 2008-04-23 | 財団法人微生物化学研究会 | Preventive and therapeutic agent for diarrhea |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT165327B (en) * | 1940-04-19 | 1950-02-10 | Hoffmann La Roche | Process for the preparation of pantothenic acid |
US4331594A (en) * | 1978-10-16 | 1982-05-25 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2856421A (en) * | 1955-09-06 | 1958-10-14 | Abbott Lab | Crystalline salts of pantothenic acid |
US3856854A (en) * | 1972-11-20 | 1974-12-24 | R Schnettler | Process of preparing alpha-hydroxymethyl aminoacids |
-
1989
- 1989-05-23 JP JP1127846A patent/JP2837870B2/en not_active Expired - Lifetime
-
1990
- 1990-05-17 US US07/524,576 patent/US5098935A/en not_active Expired - Lifetime
- 1990-05-21 DE DE90109658T patent/DE69005899T2/en not_active Expired - Fee Related
- 1990-05-21 EP EP90109658A patent/EP0399444B1/en not_active Expired - Lifetime
- 1990-05-22 CA CA002017276A patent/CA2017276C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT165327B (en) * | 1940-04-19 | 1950-02-10 | Hoffmann La Roche | Process for the preparation of pantothenic acid |
US4331594A (en) * | 1978-10-16 | 1982-05-25 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, vol. 80, no. 25, June 24, 1974, Columbus, Ohio, USA; Z.J. KAMINSKI et al. "Preparation of N-acyl-alpha-alkyl serines by selective cleavage of 5-acylamino-5-alkyl-4-oxo-1,3-dioxanes", page 439, column 1, abstract no. 146 088h; & Synthesis 1974,(4), 292-3. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0617009A1 (en) * | 1992-10-15 | 1994-09-28 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Novel amino acid derivative |
EP0617009A4 (en) * | 1992-10-15 | 1995-05-31 | Zaidan Hojin Biseibutsu | Novel amino acid derivative. |
Also Published As
Publication number | Publication date |
---|---|
US5098935A (en) | 1992-03-24 |
JPH02306953A (en) | 1990-12-20 |
DE69005899T2 (en) | 1994-04-28 |
JP2837870B2 (en) | 1998-12-16 |
EP0399444B1 (en) | 1994-01-12 |
DE69005899D1 (en) | 1994-02-24 |
CA2017276A1 (en) | 1990-11-23 |
CA2017276C (en) | 1996-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0271581A1 (en) | Novel compounds dc-88a and dc-89a1 and process for their preparation | |
US4316011A (en) | Rhodomycin antibiotics | |
US5278052A (en) | Process for the simultaneous production of benanomicins A and B | |
US5290698A (en) | Streptoverticillium ferm P-10489 which produces antitumor agent BE-13793C | |
US5096924A (en) | Anticancer antibiotic mi43-37f11 substance | |
EP0318056A2 (en) | Novel antibiotics and process for preparing the same | |
US5322854A (en) | Reveromycin A, method for preparing the same, and antitumor agent and antifungal agent comprising the same | |
EP0647625A1 (en) | Novel antibiotics with immunosuppressive activity, delaminomycins, and production thereof | |
EP0116690A1 (en) | Antiviral composition containing an indole-N-glycoside | |
EP0399444B1 (en) | New carcinostatic or antitumor antibiotic, conagenin, and production and uses thereof | |
US5109122A (en) | Antibiotics, dexylosylbenanomicin B | |
EP0206138B1 (en) | Anthracycline compounds, a process for their preparation and their use as medicaments | |
EP0189330B1 (en) | Antitumor antibiotics and their production | |
US5217885A (en) | Antitumor substance BE-13793C | |
CA1338184C (en) | Bu-3862t antitumor antibiotic | |
JP3124373B2 (en) | Immunosuppressant | |
EP0205981B1 (en) | A novel anti-tumor and antimicrobial compound, its microbiological preparation and its use as medicament | |
EP0721957A1 (en) | Compound ge3 | |
JPH04633B2 (en) | ||
JPH06228185A (en) | Substance d329, its derivative, production and use | |
JPH1045789A (en) | New physiologically active substance na16887, its production and use thereof | |
JPH0571234B2 (en) | ||
JPH06279481A (en) | Substance ws64826 | |
HU212160B (en) | Process for producing antitumour compound be-13793c | |
JPH035500A (en) | Novel anticancer and antibiotic substance mh563-32f1 and its production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19910321 |
|
17Q | First examination report despatched |
Effective date: 19921001 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB IT LI NL SE |
|
REF | Corresponds to: |
Ref document number: 69005899 Country of ref document: DE Date of ref document: 19940224 |
|
ITF | It: translation for a ep patent filed | ||
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
EAL | Se: european patent in force in sweden |
Ref document number: 90109658.6 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20060531 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20070508 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20070515 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20070516 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20070517 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20070516 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20070717 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20070510 Year of fee payment: 18 |
|
BERE | Be: lapsed |
Owner name: *KANEGAFUCHI KAGAKU KOGYO K.K. Effective date: 20080531 Owner name: *ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI Effective date: 20080531 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20080521 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081201 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080531 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20090119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080602 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080521 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070521 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080522 |